Research programme: infectious diseases vaccines - Finlay Institute of Cuba

Drug Profile

Research programme: infectious diseases vaccines - Finlay Institute of Cuba

Alternative Names: CV 638

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Finlay Institute of Cuba
  • Class Bacterial vaccines; Cholera vaccines; Hepatitis A vaccines; Meningococcal vaccines; Parasitic vaccines; Pneumococcal vaccines; Tuberculosis vaccines; Viral vaccines
  • Mechanism of Action Bacterial capsule modulators; Bacterial outer membrane protein modulators; Bacterial polysaccharide modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cholera
  • Research Hepatitis A; Malaria; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Pertussis; Pneumococcal infections; Sexually transmitted infections; Tuberculosis

Most Recent Events

  • 09 Jan 2017 Finlay Institute plans a phase III trial for Cholera (Prevention) in Cuba (RPCEC00000228)
  • 05 Mar 2014 Early research in Hepatitis A in Cuba (unspecified route)
  • 05 Mar 2014 Early research in Malaria in Cuba (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top